BR112014028654A2 - composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos - Google Patents

composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos

Info

Publication number
BR112014028654A2
BR112014028654A2 BR112014028654A BR112014028654A BR112014028654A2 BR 112014028654 A2 BR112014028654 A2 BR 112014028654A2 BR 112014028654 A BR112014028654 A BR 112014028654A BR 112014028654 A BR112014028654 A BR 112014028654A BR 112014028654 A2 BR112014028654 A2 BR 112014028654A2
Authority
BR
Brazil
Prior art keywords
methods
oligonucleotide
chelate complex
polypeptide
complex compositions
Prior art date
Application number
BR112014028654A
Other languages
English (en)
Inventor
Vaillant Andrew
Bazinet Michel
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014028654(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of BR112014028654A2 publication Critical patent/BR112014028654A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

resumo "composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos". é descrita uma composição farmacêutica contendo um complexo de quelato de oligonucleotídeo e pelo menos um polipeptídeo ou polipeptídeo peguilado. a presente descrição também descreve composições farmacêuticas adicionais e métodos para o tratamento de doenças incluindo infecções virais.
BR112014028654A 2012-05-18 2013-05-17 composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos BR112014028654A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (1)

Publication Number Publication Date
BR112014028654A2 true BR112014028654A2 (pt) 2017-10-10

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028654A BR112014028654A2 (pt) 2012-05-18 2013-05-17 composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos

Country Status (34)

Country Link
US (1) US9492506B2 (pt)
EP (1) EP2849798B1 (pt)
JP (1) JP2015517504A (pt)
KR (1) KR102068109B1 (pt)
CN (1) CN104349793B (pt)
AU (1) AU2013262416B2 (pt)
BR (1) BR112014028654A2 (pt)
CA (1) CA2873529C (pt)
CL (1) CL2014003134A1 (pt)
CO (1) CO7131387A2 (pt)
CR (1) CR20140527A (pt)
CY (1) CY1124345T1 (pt)
DK (1) DK2849798T3 (pt)
DO (1) DOP2014000264A (pt)
EA (1) EA035967B1 (pt)
EC (1) ECSP14027694A (pt)
ES (1) ES2873844T3 (pt)
HK (1) HK1204279A1 (pt)
HR (1) HRP20210840T1 (pt)
HU (1) HUE054875T2 (pt)
IL (1) IL235548B (pt)
LT (1) LT2849798T (pt)
MX (1) MX346239B (pt)
MY (1) MY168778A (pt)
NZ (1) NZ703095A (pt)
PH (1) PH12014502551B1 (pt)
PL (1) PL2849798T3 (pt)
PT (1) PT2849798T (pt)
RS (1) RS62030B1 (pt)
SG (1) SG11201407599SA (pt)
SI (1) SI2849798T1 (pt)
TW (1) TWI635864B (pt)
WO (1) WO2013170386A1 (pt)
ZA (1) ZA201408674B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943591B2 (en) 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
CA2872901A1 (en) 2012-05-10 2013-11-14 Adynxx, Inc. Formulations for the delivery of active ingredients
KR20150046309A (ko) 2012-08-30 2015-04-29 레플리코르 인코포레이티드 Ｂ형 간염 및 ｄ형 간염 감염증의 치료 방법
MD4760C8 (ro) 2014-07-10 2022-02-28 Replicor Inc. Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D
ES2750689T3 (es) 2014-08-15 2020-03-26 Adynxx Inc Señuelos oligonucleotídicos para el tratamiento del dolor
AU2019376079A1 (en) * 2018-11-08 2021-05-27 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
JP2005538186A (ja) * 2002-09-13 2005-12-15 レプリコール インコーポレーティッド 非配列相補性の抗ウイルス性オリゴヌクレオチド
EP1597278A4 (en) * 2003-02-26 2006-03-22 Intermune Inc COMPOSITIONS OF POLYETHYLENE GLYCOL-MODIFIED INTERFERON AND METHOD FOR THE APPLICATION THEREOF
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
CA2584207A1 (en) * 2004-10-19 2006-04-27 Replicor, Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
EP1942911A4 (en) * 2005-09-29 2009-08-19 Replicor Inc THERAPEUTIC MOLECULES AND USES THEREOF
WO2007041279A2 (en) * 2005-09-29 2007-04-12 S-Cell Biosciences, Inc. Methods to treat t-cell disorders using tisf
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
AU2008334948B2 (en) 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
AU2009221064B2 (en) * 2008-03-07 2014-12-11 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of microRNA related diseases
CA2764683A1 (en) * 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
EP2512491B1 (en) * 2009-10-16 2017-10-11 Glaxo Group Limited Hbv antisense inhibitors
SG187165A1 (en) * 2010-08-20 2013-02-28 Replicor Inc Oligonucleotide chelate complexes
KR20150046309A (ko) 2012-08-30 2015-04-29 레플리코르 인코포레이티드 Ｂ형 간염 및 ｄ형 간염 감염증의 치료 방법

Also Published As

Publication number Publication date
LT2849798T (lt) 2021-08-10
ECSP14027694A (es) 2015-12-31
US9492506B2 (en) 2016-11-15
MX346239B (es) 2017-03-13
HUE054875T2 (hu) 2021-10-28
PT2849798T (pt) 2021-05-18
CN104349793B (zh) 2017-11-10
TWI635864B (zh) 2018-09-21
AU2013262416B2 (en) 2017-05-11
CL2014003134A1 (es) 2015-02-13
SI2849798T1 (sl) 2021-08-31
DK2849798T3 (da) 2021-05-31
CA2873529A1 (en) 2013-11-21
AU2013262416A1 (en) 2014-12-18
EP2849798A4 (en) 2016-03-09
MX2014014021A (es) 2015-02-10
DOP2014000264A (es) 2015-01-31
CO7131387A2 (es) 2014-12-01
KR102068109B1 (ko) 2020-01-21
HK1204279A1 (en) 2015-11-13
CR20140527A (es) 2014-12-15
ES2873844T3 (es) 2021-11-04
PL2849798T3 (pl) 2021-10-18
MY168778A (en) 2018-12-04
CA2873529C (en) 2020-08-18
IL235548A0 (en) 2015-01-29
US20130309201A1 (en) 2013-11-21
CN104349793A (zh) 2015-02-11
CY1124345T1 (el) 2022-07-22
KR20150013309A (ko) 2015-02-04
PH12014502551A1 (en) 2015-01-21
IL235548B (en) 2019-07-31
EA035967B1 (ru) 2020-09-07
HRP20210840T1 (hr) 2021-08-06
TW201408308A (zh) 2014-03-01
EP2849798A1 (en) 2015-03-25
WO2013170386A1 (en) 2013-11-21
ZA201408674B (en) 2016-01-27
PH12014502551B1 (en) 2015-01-21
NZ703095A (en) 2016-07-29
EA201401278A1 (ru) 2015-04-30
EP2849798B1 (en) 2021-04-07
JP2015517504A (ja) 2015-06-22
RS62030B1 (sr) 2021-07-30
SG11201407599SA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
BR112014028654A2 (pt) composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112015029090A2 (pt) compostos de 3,4-di-hidroisoquinolin-2(1h)-ila
PH12014502397B1 (en) Pesticidal compositions and processes related thereto
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
BR112014025041B8 (pt) Composição farmacêutica
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
BR112014022214A2 (pt) fenólicos antibacterianos
IN2014CN00572A (pt)
CL2014003503A1 (es) Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano.
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
BR112015001096A2 (pt) derivados de di e tri-heteroaril como inibidores de agregação de proteína
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
BR112014015582A2 (pt) compostos antivirais
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
BR112015006243A2 (pt) agentes antibacterianos de fenicol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01), A61K 31/7088 (2006.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]